Bellevue Life Sciences Acquisition CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Joint Protein Central Inc. has filed a Schedule 13G reporting a 7.9% beneficial ownership stake in OSR Holdings, Inc.
SCHEDULE 13G/A: Bellevue Life Sciences Acquisition Corp. Sponsor Group Affirms Majority Stake in Amended SEC Filing
An amended Schedule 13G filing confirms that Bellevue Global Life Science Investors, LLC, BCM Europe AG, Bellevue Capital Management LLC, and Kuk Hyoun Hwang collectively maintain significant beneficial ownership in Bellevue Life Sciences Acquisition Corp.
SCHEDULE 13G/A: RiverNorth Capital Management Divests Entire Stake in Bellevue Life Sciences Acquisition Corp.
RiverNorth Capital Management, LLC has reported that it no longer holds a beneficial ownership stake in Bellevue Life Sciences Acquisition Corp., with its ownership falling to 0% as of December 31, 2024.